Keynote 689

For patients with locally advanced head and neck cancer that are eligible for surgery

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Status:

Recruiting

Phase 3 Icon

Trial Phase

The investigational immunotherapy is being studied in a large group of patients to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the investigational immunotherapy to be used safely.

Eligibility

About the Trial

All patients who enroll in the trial will receive medication while on the study.

  • 50% will receive pembrolizumab before surgery and pembrolizumab plus radiation therapy with or without cisplatin after surgery.
  • 50% will receive radiation therapy with or without cisplatin after surgery.

You will be assigned by chance (a process called randomization) to receive one of the above treatments.

Trial Purpose
35

US Trial Locations

Clinical trial sites are places such as hospitals or clinics where the trial is being conducted.

See Locations

National Trial Reference Number

NCT03765918 Read More at clinicaltrials.gov

What Can You Do Next?

If you would like to learn about this clinical trial or see if you can participate, you can:

Contact Our Trial Info Center

To learn more, call 1-888-577-8839

Discuss With Your Doctor

Print this page or Email it to your doctor to discuss at your next visit

Tip: To help with understanding of some clinical terms used on the page, select an underlined term to see what they mean.

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Condition

The disease, disorder, syndrome, illness, or injury that is being studied. Conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Head and Neck Neoplasms

Age range

18 — no age maximum

Gender(s)

All

Trial Purpose

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Important information

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

Trial Locations

    Location
    Status
  • La Jolla, California, United States, 92093-0698
    Recruiting
  • Santa Rosa, California, United States, 95403
    Recruiting
  • Aurora, Colorado, United States, 80045
    Recruiting
  • Gainesville, Florida, United States, 32610
    Recruiting
  • Boise, Idaho, United States, 83706
    Recruiting
  • Evanston, Illinois, United States, 60201
    Recruiting
  • Westwood, Kansas, United States, 66205
    Recruiting
  • Worcester, Massachusetts, United States, 01655
    Recruiting
  • Detroit, Michigan, United States, 48201
    Recruiting
  • Detroit, Michigan, United States, 48202
    Recruiting
  • Edina, Minnesota, United States, 55435
    Recruiting
  • Saint Louis, Missouri, United States, 63110
    Recruiting
  • Springfield, Missouri, United States, 65804
    Recruiting
  • Billings, Montana, United States, 59102
    Recruiting
  • Albuquerque, New Mexico, United States, 87131
    Completed
  • New York, New York, United States, 10016
    Recruiting
  • Charlotte, North Carolina, United States, 28204
    Recruiting
  • Portland, Oregon, United States, 97220
    Recruiting
  • Portland, Oregon, United States, 97239
    Recruiting
  • Easton, Pennsylvania, United States, 18045
    Recruiting
  • Pittsburgh, Pennsylvania, United States, 15212
    Recruiting
  • Sioux Falls, South Dakota, United States, 57104
    Recruiting
  • Dallas, Texas, United States, 75390
    Recruiting
  • Salt Lake City, Utah, United States, 84112
    Recruiting
  • Charlottesville, Virginia, United States, 22908
    Recruiting
  • Fairfax, Virginia, United States, 22031
    Recruiting
  • Miami, Florida, United States, 33136
    Recruiting
  • Bronx, New York, United States, 10467
    Recruiting
  • Nashville, Tennessee, United States, 37232
    Recruiting
  • Sacramento, California, United States, 95817
    Recruiting
  • Seattle, Washington, United States, 98109
    Recruiting
  • Portland, Oregon, United States, 97227
    Recruiting
  • Los Angeles, California, United States, 90033
    Recruiting
  • Baltimore, Maryland, United States, 21201
    Recruiting
  • Burlington, Vermont, United States, 05401
    Recruiting

How to Learn More

When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.

Print or email this page.

Trial reference number

A unique identification code given to each clinical trial registered on clinicaltrials.gov.

Keynote number

A unique identification code used by the sponsor to identify a specific trial.
Keynote-689

Official title

A description of the clinical trial that the trial sponsor and clinicians use to identify a specific trial and its purpose.
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Call 1-888-577-8839 to contact our trial information center

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.